| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
SKT is a Ashland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Waiting Room Solutions is a Goshen, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ReproTech is a company that specializes in long term cryostorage for fertility preservation through their nationwide network of partner Freezing Centers.
Cavapharma is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.